Generated September 17, 2026 at 8:30 PM ET
· Covers September 17 trading day
· 10 of 162 ready 8-Ks selected
· AI-assisted overview
Today's filings featured significant M&A activity: Lisata Therapeutics closed a reverse merger with Marea and secured $225M PIPE financing, while Surgery Partners completed a $797M sale of Idaho Falls hospitals to Intermountain Health. NewHold Investment Corp. III shareholders approved its business combination with newcleo, with closing expected Sept 21. In regulatory news, Ultragenyx earned FDA full approval for FAYUVI, the first treatment for Sanfilippo type A, and Stardust Power received a Nasdaq delisting notice. Debt-related filings included GMR Solutions repricing its $2.9B term loan and American Rebel issuing shares to settle debt. Fennec Pharmaceuticals reported positive Phase 2 results for PEDMARK in Japan.
LSTA
LISATA THERAPEUTICS, INC.
M&A
negative
materiality 0.95
September 17, 2026, 9:27 AM ET
Lisata closes Marea reverse merger; $225M PIPE financing
- Merger closed Sept 17, 2026; Marea stockholders get 1,793,129 LSTA shares + 211,365 Series C preferred (convertible to common).
- $225M PIPE: 150,867.995 Series C preferred shares sold to investors; expected close Sept 18, 2026.
- Post-deal ownership: LSTA legacy holders ~2.39%, Marea holders ~59.54%, PIPE investors ~38.07% (on conversion).
SGRY
Surgery Partners, Inc.
M&A
positive
materiality 0.90
September 17, 2026, 9:03 AM ET
Surgery Partners closes $797M sale of Idaho Falls hospitals to Intermountain; updates guidance
- Closed sale of Idaho Falls hospitals to Intermountain Health for $797M gross / $587M net cash proceeds; $1.15B enterprise value.
- Multiples: ~7x LTM adjusted EBITDA and ~17x avg 3-yr distributions; proceeds primarily to pay down debt.
- Leverage expected to improve 30bps from 4.4x at Q2 2026; transaction accretive to adjusted earnings growth annually.
NHIC
NewHold Investment Corp. III
M&A
positive
materiality 0.85
September 17, 2026, 4:45 PM ET
NewHold shareholders approve business combination with newcleo plc; close expected Sept 21
- Business Combination Proposal passed 19,986,437 votes for vs 1,286,410 against (2 abstentions).
- Merger Proposal passed 19,986,439 for vs 1,286,410 against; 77.04% of shares (21,272,849) represented.
- ~93.4% of votes cast favored combination, equal to ~72.4% of outstanding shares.
regulatory
negative
materiality 0.80
September 17, 2026, 5:00 PM ET
Stardust Power receives Nasdaq delisting notice for bid price below $1.00
- Received Nasdaq notice on Sept 11, 2026: common stock bid price below $1.00 for 30 straight business days (July 30–Sept 10).
- 180-day compliance period ends March 10, 2027; must close at $1.00+ for 10 consecutive business days to regain compliance.
- Also under earlier April 24, 2026 notice for failing $35M market value of listed securities; cure deadline Oct 21, 2026.
RARE
Ultragenyx Pharmaceutical Inc.
regulatory
positive
materiality 0.80
September 17, 2026, 3:55 PM ET
Ultragenyx gets FDA standard full approval for FAYUVI, first Sanfilippo type A treatment
- FDA granted standard full approval of FAYUVI (UX111) for pediatric MPS IIIA (Sanfilippo syndrome type A) on Sept 17, 2026.
- FAYUVI is the first-ever FDA-approved treatment for Sanfilippo syndrome type A, a progressive fatal neurodegenerative disease.
- This is Ultragenyx's second gene therapy approval; company received a Priority Review Voucher upon approval.
FFAI
FARADAY FUTURE INTELLIGENT ELECTRIC INC.
regulatory
positive
materiality 0.80
September 17, 2026, 9:05 AM ET
Faraday Future regains Nasdaq equity compliance; EAI robot sales hit 552 units
- Regained compliance with Nasdaq $2.5M equity standard as of July 31, 2026, after Q2 equity was $1.412M.
- Reduced notes payable by ~$10.0M, derivative call option liability by ~$5.8M, and accounts payable/accrued liabilities by ~$15.3M.
- Employee-related liabilities cut $13.5M; legacy vendor payables cleaned up by $2.5M.
WGRX
Wellgistics Health, Inc.
litigation
positive
materiality 0.80
September 17, 2026, 5:23 PM ET
DataMEDS AI settles lawsuits, pays $450K, extinguishes ~$19M liability
- Settlement with Brian Norton, RxERP, Nomad, Strategix and others resolves Florida and Delaware suits.
- Company paid $450,000: $350,000 to repurchase and extinguish 364,099 common shares; $100,000 for MIPA claims.
- Agreement extinguishes approximately $19 million in liability from the consolidated balance sheet.
AREB
AMERICAN REBEL HOLDINGS INC
debt
negative
materiality 0.80
September 17, 2026, 1:42 PM ET
American Rebel issues 2.1M shares for ~$211K debt; COO contract extended to 2029
- Streeterville exchanged $93K Partitioned Note for 697,674 shares at $0.1333 on Sept 15.
- 1800 Diagonal converted $78,236.41 principal into 879,340 shares at $0.081-0.1055 across Sept 14-15.
- Silverback Capital requested 500,000 shares on Sept 15 for a $39,390 payment.
debt
positive
materiality 0.65
September 17, 2026, 4:54 PM ET
GMR Solutions reprices $2.9B term loan, repays $200M, cuts rate 50bps
- Repriced all $2.9B Term Loan B due Oct 2032; repaid $200M cash, principal now ~$2.7B.
- Interest rate margin reduced from SOFR+325bps to SOFR+275bps (50bp cut).
- Expects ~$28M annual cash interest expense savings; no new debt incurred.
FENC
FENNEC PHARMACEUTICALS INC.
other material
positive
materiality 0.85
September 17, 2026, 4:03 PM ET
Fennec's PEDMARK hits primary endpoint in Japan Phase 2, 24% hearing loss vs 56.4%
- Phase 2 STS-J01 met primary endpoint: ASHA-defined hearing loss 24.0% (6/25) vs 56.4% historical benchmark (P=0.001).
- No Grade 3/4 hearing loss by Brock criteria; 84.0% Grade 0 hearing loss.
- Objective tumor responses in 23/24 evaluable patients (95.8%), no interference with cisplatin antitumor activity.